Rep. Kevin Hern has recorded five trades in Boston Scientific ahead of the medical device company's Q3 earnings on October 28. The filings place him at the center of congressional interest in healthcare names reporting soon, with additional activity in IQV and four separate trades in Home Depot before its November 17 release.
Analysts project BSX to deliver roughly $0.78 EPS on approximately $5.2 billion in revenue. That compares to the company's Q2 beat where it posted $0.86 EPS against a $0.81 consensus and $5.44 billion in sales. Public sentiment tracked on X points to the upcoming print as a pivotal test for the stock, which trades at its lowest P/E multiple since 2020 amid moderating growth in cardiology products like Watchman and competition from Medtronic. Hern's pattern of engagement in BSX and peer IQV suggests lawmakers are positioned for resilience in med-tech despite some recent estimate pressure.
Home Depot carries a consensus EPS target near $3.87 on revenue of about $42.8 billion for its fiscal Q3. The retailer beat estimates in its most recent quarter with $4.92 EPS, building on prior-year Q3 results of $3.74 EPS. Hern's four trades there add to a broader slate that includes three transactions each in AAPL, ITW and ROK, indicating a tilt toward industrials, technology and consumer cyclical sectors that report through mid-November. Pete Sessions also appears in the AAPL filings, marking one of the few bipartisan overlaps in the latest data.
The 21 additional trades tied to Hern, Sheri Biggs, Max Miller and Richard Blumenthal further amplify the earnings-watch signal across unspecified positions. With no buys or sells dominating the summary counts, the activity reflects positioning rather than outright exits. Full-year forecasts for BSX show EPS climbing toward $3.30 while HD eyes roughly $15 per share for its fiscal 2027, offering a longer runway if upcoming prints meet or exceed targets.
This clustering before key releases continues a pattern visible in recent weeks but with fresh emphasis on Hern's healthcare and retail exposure. The timing is notable given how closely it tracks the earnings calendar and consensus figures.
This is data analysis, not financial advice.
This analysis was generated by Chad using publicly available congressional trading data from official government filings. This is not financial advice. All data is sourced from senate.gov, clerk.house.gov, and SEC EDGAR.